37 results about "Adrenal Cushing's syndrome" patented technology

The invention relates to a method for treating Cushing's syndrome in a patient, which method comprises administering the patient with a pharmaceutical composition comprising a glucocorticoid receptor antagonist, at least twice a day, or an extended-release composition of a glucocorticoid receptor antagonist, or a combination of a glucocorticoid receptor antagonist and a inhibitor of cortisol synthesis.

The present invention is directed to imidazolyl derivatives of the formula: where the substituents are defined in the specification, or a pharmaceutically acceptable salt thereof. The derivatives bind selectively to the somatostatin subtype receptors and elicit either an agonist or antagonist effect from the somatostatin subtype receptors. The derivatives are useful for treating a variety of diseases including acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas.

The invention provides a method for diagnosing a disorder or disease associated with an imbalance of monoamines in a subject, or of diagnosing susceptibility of the subject to the same, wherein the method comprising (a) providing a sample from a subject to be tested, (b) measuring the levels of dopamine, melatonin and / or serotonin in the sample; and (c) comparing the levels measured in step (b) with levels of dopamine, melatonin and / or serotonin associated with a reference population of subjects, wherein a difference in one or more of the levels measured in step (b) with the levels of dopamine, melatonin and serotonin associated with the reference population of subjects is indicative of a positive diagnosis. The invention further provides a method of prevention or treatment of a disorder or disease associated with an imbalance of monoamines, and kits for the same.

The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng / mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng / mL.

We disclose a diagnostic test to determine suitable therapeutic intervention of subjects suffering from subclinical Cushing's syndrome [SCS] and also agents that antagonize the action of cortisol or inhibit excess cortisol production in the treatment of conditions such as SCS in the presence of an adrenal incidentaloma.

Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and / or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.

The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and / or prophylaxis of disease associated to an excess of glucocorticoids. In particular, the invention relates to the use of novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues for treating Cushing's syndrome, iatrogenic hypercortisolism or depression. Also the present invention is related to methods of preparing the novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues.

The invention discloses application of mesenchymal stem cells in preparation of products for treating rheumatoid arthritis. The invention provides application of the mesenchymal stem cells or cell preparations of the mesenchymal stem cells in preparation of drugs for treatment of rheumatoid arthritis. The preparation method of the cell preparations includes the following steps: adopting a tissue block in a Warton zone of the umbilical cord as a raw material, and preparing the umbilical cord mesenchymal stem cells so as to obtain the cell preparations, wherein a low-serum culture medium is adopted in the preparation process. The cell preparations are suitable for cell therapy of rheumatoid arthritis and other diseases related to rheumatoid arthritis, wherein complications and diseases withsimilar pathogenesis of the diseases related to rheumatoid arthritis include rheumatoid vasculitis, pneumonia, osteoarthritis, rheumatoid heart disease, ankylosing spondylitis, gout, eye diseases, kidney diseases, urinary system infection, Cushing's syndrome, oral ulcers and other diseases. A great application value is provided for treatment of rheumatoid arthritis and related diseases.

The present disclosure relates to treatment and management of Cushing's syndrome, Headache disorders and Neuropathic using a composition comprising asiaticoside and madecasosside optionally along with at least one excipient. The treatment can be extended to Myalgia and other related disease conditions.

This invention relates to the use of a plant extract, derived from a Salvia spp, comprising one or more tanshinone compounds, or said one or more tanshinone compounds, in the treatment of wounds, particularly chronic wounds, or other conditions benefiting from inhibition of Cortisol production, particularly Cushing's syndrome. Preferred tanshinone compounds include, but are not limited to, dihydrotanshinone (particularly 15,16- dihydrotanshinone (CAS No. 87205-99-0) ) and Tanshinone I.

Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC) and / or Cushing's syndrome. Such methods involve administration of an agent which exhibits an IC50 value against huACAT1 of less than 10 μM, and one or more further characteristics including effects on adrenocortical cells, disruption of cholesterol homeostasis, reduction in steroid biosynthesis, reduction of mitochondrial function, and / or preferential binding to by low-density lipoprotein (LDL).

This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushing's Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushing's Disease.

Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and / or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.

The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improveby modulation of androgen receptor and / or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases,cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

The present invention relates to novel dihydropyridine derivatives of formula (I):as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and / or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and / or prophylaxis of disease associated to an excess of glucocorticoids. In particular, the invention relates to the use of novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues for treating Cushing's syndrome, iatrogenic hypercortisolism or depression. Also the present invention is related to methods of preparing the novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues.

The invention discloses a medicine for treating Cushing's syndrome. The medicine is characterized by consisting of the following components: radix et rhizoma rhei, mirabilite, cortex magnoliae officinalis, aurantii fructus immaturus, radix polygoni multiflori, radix gentianae and rhizoma polygonati, wherein the weights of the components are as follows: 6g of the radix et rhizoma rhei, 6g of the mirabilite (mixed with water), 6g of the cortex magnoliae officinalis, 6g of the aurantii fructus immaturus, 15g of the radix polygoni multiflori, 15g of the radix gentianae and 15g of the rhizoma polygonati; and preparing and taking methods comprise the following steps: one dose every day, decocting the components in water twice, filtering and reserving 300-400ml of medicine liquid, taking the medicine liquid on an empty stomach when the medicine liquid is warm in three times and taking the mirabilite which is mixed with water by 2g in each time, 5 doses every week, and stopping taking for 2d, wherein the turn of conducting continuous treatment for 8 weeks and taking rest for 2 weeks is a treatment course. The medicine can solve the problems of an existing Cushing's syndrome treating medicine which is high in side effects, long in administration duration, high in recurrence rate after being stopped and the like; and the medicine is suitable for treating the Cushing's syndrome.

Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing's syndrome.

Methods are provided for treatment of disorders associated with excess cortisol production, including, but not limited to, treatment of Cushing's syndrome. Such methods involve administration of a therapeutically effective amount of a combination of: (a) an inhibitor of CYP11B1; and (b) ACAT1 inhibitor N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethyl-lamino)phenyl)cyclopentyl)-methyl)urea or a salt thereof; or (a) an inhibitor of CYP11B1; (b) an inhibitor of CYP11B2; and (c) ACAT1 inhibitor N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethyl-lamino)phenyl)cyclopentyl)-methyl)urea or a salt thereof.

The present invention discloses a ulipristal acetate compound (the chemical name of 17alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregn-4,9-diene-3,20-dione and the English name of Ulipristal acetate) crystal form K, a preparation method, a composition and uses thereof, particularly a ulipristal acetate crystal form K solid substance state form under a solid state, a preparation of the crystal form K solid substance sample, and applications of the ulipristal acetate crystal form K substance as the pharmaceutical active ingredient in preparation of pregnancy prevention drugs 120 h after various unprotected sex behaviors or contraceptive failure, and drugs for treatment of uterine fibroids, endometriosis, cushing's syndrome, glaucoma.

Novel methods of treating tumors, including neuroendocrine tumors (NET), such as a catecholamine-secreting tumor (CST), are disclosed. The methods include treating Cushing's syndrome in a Cushing's syndrome patient having a NET, such as a CST. Tumors may be treated with a glucocorticoid receptor (GR) modulator (GRM), such as a GR antagonist (GRA). The novel treatments may treat Cushing's syndrome,may reduce catecholamine production by the tumor, may reduce catecholamine excess, may ameliorate symptoms of catecholamine excess, and may improve the efficacy of alpha- or beta-adrenergic blockade,somatostatin or somatostatin analog treatment or imaging, or Peptide Receptor Radionuclide Therapy, in patients with a CST. The GRM may reduce the activation of a GR, and may bind to a GR with higheraffinity than it binds to a progesterone receptor (PR). In embodiments, the drug may only poorly bind to PR, or may not measurably bind to PR.

To provide an antineutrophilia agent effective for treatment of development and progress of acute infections, collagen diseases (chronic rheumatoid arthritis, Wegener's granulomatosis and Behcet's disease), chronic obstructive pulmonary disease (COPD), chronic bronchitis, pulmonary emphysema, small airway disease, gout, Cushing's syndrome, myelofibrosis, neoplastic neutrophilia, polycythemia vera and diseases caused by administration of steroid drugs. An antineutrophilia agent containing a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmaceutically acceptable salt thereof [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl group].

The present invention relates to novel dihydropyridine derivatives of formula (I):as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and / or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.